These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25532827)

  • 21. Selection of HBV key reactivation factors based on maximum information coefficient combined with cosine similarity.
    Yuan G; Zhai Y; Tang J; Zhou X
    Technol Health Care; 2024; 32(2):749-763. PubMed ID: 37393455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decision Tool for Herpes B Virus Antiviral Prophylaxis after Macaque-Related Injuries in Research Laboratory Workers.
    Barkati S; Taher HB; Beauchamp E; Yansouni CP; Ward BJ; Libman MD
    Emerg Infect Dis; 2019 Sep; 25(9):. PubMed ID: 31441751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fatal case of HBV-liver failure after withdrawal of antiviral treatment.
    Castellote J; García Guix M; Amador Navarrete A; Rota Roca R; Baliellas Comellas C
    Rev Esp Enferm Dig; 2024 Jan; ():. PubMed ID: 38205696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does currently recommended maternal antiviral prophylaxis against mother-to-child transmission of hepatitis B virus require enhancement?
    Zhou YH; Zhao H
    JHEP Rep; 2023 Nov; 5(11):100831. PubMed ID: 37791377
    [No Abstract]   [Full Text] [Related]  

  • 25. Reply to: "Does currently recommended maternal antiviral prophylaxis against mother-to-child transmission of hepatitis B virus require enhancement?".
    Matthews PC; Ocama P; Wang S; El-Sayed M; Turkova A; Ford D; Torimiro J; Garcia Ferreira AC; Miranda AE; De La Hoz Restrepo FP; Seremba E; Mbu R; Pan CQ; Razavi H; Dusheiko G; Spearman CW; Hamid S
    JHEP Rep; 2023 Nov; 5(11):100875. PubMed ID: 37822785
    [No Abstract]   [Full Text] [Related]  

  • 26. Reply to: "Association between antiviral treatments and fracture in elderly patients with HBV needs further evaluation".
    Lai JC; Yip TC; Wong GL
    J Hepatol; 2024 Sep; 81(3):e110-e111. PubMed ID: 38763357
    [No Abstract]   [Full Text] [Related]  

  • 27. Association between antiviral treatments and fracture in elderly patients with HBV needs further evaluation.
    Wu JL; Luo JY; Jiang ZB
    J Hepatol; 2024 Sep; 81(3):e108-e109. PubMed ID: 38527526
    [No Abstract]   [Full Text] [Related]  

  • 28. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
    Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
    J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
    Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
    Bannuru RR; Schmid CH; Kent DM; Vaysbrot EE; Wong JB; McAlindon TE
    Ann Intern Med; 2015 Jan; 162(1):46-54. PubMed ID: 25560713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.
    Navarro Coy NC; Brown S; Bosworth A; Davies CT; Emery P; Everett CC; Fernandez C; Gray JC; Hartley S; Hulme C; Keenan AM; McCabe C; Redmond A; Reynolds C; Scott D; Sharples LD; Pavitt S; Buch MH
    BMC Musculoskelet Disord; 2014 Dec; 15():452. PubMed ID: 25539805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
    Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
    Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.
    Nard FD; Todoerti M; Grosso V; Monti S; Breda S; Rossi S; Montecucco C; Caporali R
    World J Hepatol; 2015 Mar; 7(3):344-61. PubMed ID: 25848463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
    Kohli A; Osinusi A; Sims Z; Nelson A; Meissner EG; Barrett LL; Bon D; Marti MM; Silk R; Kotb C; Gross C; Jolley TA; Sidharthan S; Petersen T; Townsend K; Egerson D; Kapoor R; Spurlin E; Sneller M; Proschan M; Herrmann E; Kwan R; Teferi G; Talwani R; Diaz G; Kleiner DE; Wood BJ; Chavez J; Abbott S; Symonds WT; Subramanian GM; Pang PS; McHutchison J; Polis MA; Fauci AS; Masur H; Kottilil S
    Lancet; 2015 Mar; 385(9973):1107-13. PubMed ID: 25591505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.
    Hochberg MC; Martel-Pelletier J; Monfort J; Möller I; Castillo JR; Arden N; Berenbaum F; Blanco FJ; Conaghan PG; Doménech G; Henrotin Y; Pap T; Richette P; Sawitzke A; du Souich P; Pelletier JP;
    Ann Rheum Dis; 2016 Jan; 75(1):37-44. PubMed ID: 25589511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-α inhibitor.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Im JP; Park DI; Eun CS; Jung SA; Shin JE; Lee KM; Cheon JH
    Scand J Gastroenterol; 2015 Mar; 50(3):312-20. PubMed ID: 25581784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.
    Obach D; Yazdanpanah Y; Esmat G; Avihingsanon A; Dewedar S; Durier N; Attia A; Anwar WA; Cousien A; Tangkijvanich P; Eholié SP; Doss W; Mostafa A; Fontanet A; Mohamed MK; Deuffic-Burban S
    Hepatology; 2015 Jul; 62(1):31-9. PubMed ID: 25581111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.
    Westhovens R; Robles M; Ximenes AC; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Murthy B
    Ann Rheum Dis; 2015 Mar; 74(3):564-8. PubMed ID: 25550337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
    Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
    J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral treatment among pregnant women with chronic hepatitis B.
    Fan L; Owusu-Edusei K; Schillie SF; Murphy TV
    Infect Dis Obstet Gynecol; 2014; 2014():546165. PubMed ID: 25548510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.